NORDIMET (methotrexate) - Moderate plaque psoriasis
Reason for request
Summary of opinion
Favourable opinion for reimbursement in moderate plaque psoriasis in adults who are candidates for systemic therapy.
No clinical added value of NORDIMET 25 mg/ml (methotrexate) solution for injection in pre-filled pen in the care pathway for the treatment of moderate plaque psoriasis in adults who are candidates for systemic therapy compared to other medicinal products containing methotrexate.
Clinical Benefit
| Substantial |
The clinical benefit of NORDIMET 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg (methotrexate) solution for injection in pre-filled pen is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that NORDIMET 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg (methotrexate) solution for injection in pre-filled pen provides no clinical added value (CAV V) in the care pathway for the treatment of moderate plaque psoriasis in adults who are candidates for systemic therapy compared to the other medicinal products containing methotrexate. |
